Revelation Biosciences (REVB) Total Liabilities (2020 - 2026)
Revelation Biosciences (REVB) posted quarterly Total Liabilities of $2.7 million for Q4 2025, up 42.24% year-over-year from $1.9 million in Q4 2024, and up 46.77% quarter-over-quarter from $1.9 million in Q3 2025.
Revelation Biosciences (REVB) Total Liabilities (2020 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Total Liabilities for 6 consecutive years, with $2.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities rose 42.24% year-over-year to $2.7 million; the TTM figure through Dec 2025 stood at $2.7 million (up 42.24% YoY), while the FY2025 annual figure was $2.7 million, up 42.24% from the prior year.
- Total Liabilities grew to $2.7 million in Q4 2025 per REVB's latest filing, from $1.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $11.1 million in Q2 2024 and bottomed at $1.1 million in Q1 2025.
- Historically, Total Liabilities has averaged $4.8 million across 5 years, with a median of $4.8 million in 2021.
- Annual changes were most pronounced in 2024 — Total Liabilities soared 140.68% — and 2025, when it slumped 85.9%.
- Revelation Biosciences' Total Liabilities stood at $2.1 million in 2021, then jumped by 107.83% to $4.5 million in 2022, then gained by 25.03% to $5.6 million in 2023, then slumped by 65.61% to $1.9 million in 2024, then soared by 42.24% to $2.7 million in 2025.
- Business Quant data shows REVB's Total Liabilities at $2.7 million in Q4 2025, $1.9 million in Q3 2025, and $1.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | 2.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.43 Mn |
| Dec 31, 2025 | 2.72 Mn |
| Sep 30, 2025 | 1.85 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 4.07 Mn |
| Jun 30, 2024 | 11.13 Mn |
| Mar 31, 2024 | 5.23 Mn |
| Dec 31, 2023 | 5.56 Mn |
| Sep 30, 2023 | 5.40 Mn |
| Jun 30, 2023 | 4.62 Mn |
| Mar 31, 2023 | 8.10 Mn |
| Dec 31, 2022 | 4.45 Mn |
| Sep 30, 2022 | 4.37 Mn |
| Jun 30, 2022 | 6.00 Mn |
| Mar 31, 2022 | 8.08 Mn |
| Dec 31, 2021 | 2.14 Mn |
| Sep 30, 2021 | 6.65 Mn |
| Jun 30, 2021 | 6.22 Mn |